Law360, New York (September 5, 2008, 12:00 AM EDT) -- In the latest salvo over generic versions of the cancer drug Thalomid, generic-drug maker Barr Laboratories Inc. said on Thursday that Celgene Corp.'s patent claims are unenforceable because the inventor withheld material information as the application wended its way through the U.S. Patent and Trademark Office.
Barr's answer to Celgene's patent lawsuit in the U.S. District Court for the District of New Jersey alleged that the patents "are unenforceable due to inequitable conduct."
The patents at issue in the suit, U.S. Patent Numbers 5,629,327 and 6,235,756,...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.